Table 1 Relationship between the BRAF V600E mutation and clinicopathologic factors in papillary thyroid microcarcinoma
Total, n(%) | BRAFV600Emutation, n (%) | ||||
|---|---|---|---|---|---|
Mutant (n = 72) | Wild (n = 29) | χ 2 | P value | ||
Age | 0.862 | 0.353 | |||
<45 years | 25(24.8) | 16(22.2) | 9(31.0) | ||
≥45 years | 76(75.2) | 56(77.8) | 20(69.0) | ||
Gender | 0.669 | 0.413 | |||
Female | 90(89.1) | 63(87.5) | 27(93.1) | ||
Male | 11(10.9) | 9(12.5) | 2(6.9) | ||
Multifocality | 0.002 | 0.962 | |||
No | 70(69.3) | 50(69.4) | 20(69.0) | ||
Yes | 31(30.7) | 22(30.6) | 9(31.0) | ||
Extrathyroidal extension | 0.119 | 0.73 | |||
No | 48(47.5) | 35(48.6) | 13(44.8) | ||
Yes | 53(52.5) | 37(51.4) | 16(55.2) | ||
Hashimoto thyroiditis | 0.804 | 0.37 | |||
Not combined | 79(78.2) | 58(80.6) | 21(72.4) | ||
Combined | 22(21.8) | 14(19.4) | 8(27.6) | ||
T staging | 1.128 | 0.569 | |||
T1a | 48(47.5) | 36(50.0) | 12(41.4) | ||
T3 | 52(51.5) | 35(48.6) | 17(58.6) | ||
T4a | 1(1.0) | 1(1.4) | 0(0) | ||
Nodal metastasis | 2.973 | 0.226 | |||
N0 | 83(82.2) | 61(84.7) | 22(75.9) | ||
N1a | 11(10.9) | 8(11.1) | 3(10.3) | ||
N1b | 7(6.9) | 3(4.2) | 4(13.8) | ||
Distant metastasis | 2.508 | 0.113 | |||
No | 100(99.0) | 72(100.0) | 28(96.6) | ||
Yes | 1(1.0) | 0(0.0) | 1(3.4) | ||